Corona Remedies Ltd reported a 44 percent rise in consolidated profit after tax for the fourth quarter ended March 2026 and announced a final dividend of ₹10 per equity share for FY26, as the Ahmedabad-based pharmaceutical company benefited from strong sales growth and improved operating efficiencies.
The company recommended a final dividend of ₹10 per equity share of face value ₹10 each, translating into a 100% payout for shareholders, subject to approval at the upcoming annual general meeting. Revenue for the fourth quarter of FY26 rose 20.2 percent year-on-year, driven by brand-building initiatives and portfolio expansion, while profit growth was supported by operating leverage and cost optimisation measures.
For the full financial year FY26, revenue from operations increased 17.3 percent to Rs 1,403 crore from Rs 1,196 crore a year ago. Consolidated profit after tax rose 20.9 per cent to ₹240 crore from ₹198.5 crore in FY25. The India-focused branded pharmaceutical company said it continued to strengthen its portfolio during the year through new launches, relaunches and acquisitions.
“FY26 has been a strong year for Corona Remedies, marked by consistent revenue growth and enhanced operational efficiency,” Nirav K. Mehta, managing director and chief executive officer of Corona Remedies, stated in an official release. “Our strategic focus on brand building, specialty segments like biosimilars and infertility and portfolio expansion through acquisitions continues to strengthen our competitive positioning,” Mehta added. The company said two of its brands crossed ₹100 crore in moving annual turnover revenue during FY26, reflecting strengthening brand equity. It also improved its market ranking to 27th in India, continuing its steady climb in the domestic pharmaceutical market.
The record date for the final dividend has been fixed as June 19, while the dividend, if approved by shareholders, will be paid on or before August 7.